Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder

Basit Öğe Kaydı
dc.authorscopusid6602989482
dc.authorscopusid6602230610
dc.authorscopusid6602404106
dc.authorscopusid58525631800
dc.authorscopusid58525850000
dc.authorscopusid6505501358
dc.authorscopusid58525179700
dc.contributor.authorFagiolini, Andrea
dc.contributor.authorCardoner, Narcis
dc.contributor.authorPirildar, Sebnem
dc.contributor.authorIttsakul, Pichai
dc.contributor.authorNg, Bernardo
dc.contributor.authorDuailibi, Kalil
dc.contributor.authorEl Hindy, Nasser
dc.date.accessioned2024-08-25T18:46:02Z
dc.date.available2024-08-25T18:46:02Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractIntroductionMental health disorders, especially depressive and anxiety disorders, are associated with substantial health-related burden. While the second-generation antidepressants are widely accepted as first-line pharmacological treatment for major depressive disorder (MDD), patient response to such treatment is variable, with more than half failing to achieve complete remission, and residual symptoms are frequently present.Areas coveredHere, the pharmacodynamics of venlafaxine XR are reviewed in relation to its role as both a selective serotonin reuptake inhibitor (SSRI) and a serotonin-norepinephrine-reuptake inhibitor (SNRI), and we look at how these pharmacodynamic properties can be harnessed to guide clinical practice, asking the question 'is it possible to develop a symptom-cluster-based approach to the treatment of MDD with comorbid anxiety utilizing venlafaxine XR?.' Additionally, three illustrative clinical cases provide practical examples of the utility of venlafaxine-XR in real-world clinical practice. The place of venlafaxine XR in managing fatigue/low energy, a frequent residual symptom in MDD, is explored using pooled data from clinical trials of venlafaxine XR.Expert opinionVenlafaxine XR should be considered as a first-line treatment for MDD with or without comorbid anxiety, and there are clear pharmacodynamic signals supporting a symptom cluster-based treatment paradigm for venlafaxine XR.en_US
dc.description.sponsorshipViatrisen_US
dc.description.sponsorshipThis manuscript was funded by Viatris.en_US
dc.identifier.doi10.1080/14656566.2023.2242264
dc.identifier.issn1465-6566
dc.identifier.issn1744-7666
dc.identifier.pmid37501324en_US
dc.identifier.scopus2-s2.0-85166908374en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1080/14656566.2023.2242264
dc.identifier.urihttps://hdl.handle.net/11454/101784
dc.identifier.wosWOS:001043565900001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofExpert Opinion On Pharmacotherapyen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240825_Gen_US
dc.subjectVenlafaxineen_US
dc.subjectmajor depressive disorderen_US
dc.subjectmonoaminesen_US
dc.subjectsymptom clustersen_US
dc.subjectdepressionen_US
dc.subjectanxietyen_US
dc.subject>en_US
dc.subjectStar-Asterisk-Den_US
dc.subjectResidual Symptomsen_US
dc.subjectExtended-Releaseen_US
dc.subject2nd-Generation Antidepressantsen_US
dc.subjectCanadian Networken_US
dc.subjectOpen-Labelen_US
dc.subjectOutpatientsen_US
dc.subjectGuidelinesen_US
dc.subjectEfficacyen_US
dc.subjectMooden_US
dc.titleMoving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorderen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu